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INTRODUCTION
ince 1957, when fluoropyrimidine derivative 5-Fluorouracil
(5-FU) was synthesized, up to nowadays, this chemothera-
peutic agent has been widely used for treatment of patients with
colorectal cancer. During last 45 years majority of investigational
efforts has been directed towards increase of 5-FU efficacy.
During 1960 and 1970, 5-FU was used mostly as monotherapy
with response rate 8% to 85%, as reported in literature. Other
drugs, like nitrosourea derivatives and mitomycin C did not man-
age to increase efficacy when used in combination with 5-FU
(MOF, BOF etc.) (1). In 1980, certain progress was achieved
thanks to 5-FU biomodulation and 5-FU based therapeutic regi-
mens. Continuous infusion enabled significant increase of
response rate and modest improvement in overall survival (2).
Numerous substances were used as 5-FU biomodulators with dif-
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Xeloda as first-line therapy of metastatic
colorectal cancer - our experience
S
BACKGROUND: Results of phase III clinical studies comparing efficacy of Xeloda vs.
standard 5-FU/FA protocols as first line therapy of metastatic colorectal carcinoma
(MCRC), have shown better efficacy of Xeloda, with less toxic adverse effects, apart
from hand-foot syndrome. 
METHODS: From January 2000 to May 2001 the study enrolled 54 patients with MCRC,
38 males and 16 females, aged 30-78 years. All patients had metastatic diseases. In
33 the primary tumor was in colon, in 21 in rectum. All patients received Xeloda 2500
mg/m2/day in two daily doses, during 14 days followed by 7 days of pause. Dose inten-
sity was 88,79% +/- 9,2. For efficacy evaluation the WHO criteria and tumor markers
CEA and CA 19-9 were used. 
RESULTS: Overall response rate was 47%, with 13% complete responses, 34% partial
responses, 38% stable disease and 15% disease progression. No significant difference
was found between patients with regard to localization of primary tumor (colon or rec-
tum). There was no significant difference in response rate when compared 27 patients
with adverse events of capecitabine (’hand and foot’ syndrome and diarrhea) and those
without them. Response rate in a subgroup of 21 evaluable (out of 29) patients with
initial signs of liver dysfunction was worse (p<0.005) in comparison with patients with
normal liver function. Most frequent adverse events were ’hand and foot’ syndrome
(52%) and diarrhea (24%), or both (14%). Other adverse events, up to grade 2 toxici-
ty, were sporadically reported; however, hematological toxicity was significantly more
common in a subgroup of patients with compromised liver function (p<0.007).
CONCLUSION: This study has shown that Xeloda is a good monotherapy choice, with
high response rate as first line therapy of metastatic CRC. Adverse events do not influ-
ence response. Liver dysfunction is a poor prognostic parameter. Therapy with Xeloda
is convenient and relatively safe in patients with liver dysfunction, where administration
of other cytotoxic agents is not possible.
KEY WORDS: Colorectal Neoplasms; Antimetabolites; Antineoplastic; Combined
Chemotherapy Protocols; Neoplasm Metastasis; Treatment Outcome
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249ferent success. Most of them were withdrawn as ineffective (3).
Only biomodulation with leucovorin proved to be effective as
shown by increased response rate, but without significant influ-
ence on overall survival (4), and, as such, it was introduced in
most of the standard therapeutic regimens. That is how well
known and commonly used therapeutic schemes, Mayo Clinic, de
Gramon, Roswell Park, AIO Geman, Ardalan, have became stan-
dard protocols. During 1990 there were several new agents with
mechanism of action different from thymidylate synthetase inhi-
bition, with irinotecan and oxaliplatina among them. These drugs
have brought important improvement in patients’ survival, when
used as first line therapy in combination with 5-FU or as
monotherapy in second-line treatment of metastatic disease.
Combination with oxaliplatin enabled tumor resectability in 50% of
patients with primary unresectable liver metastases (5). Further
progress in therapy of CRC was made by development of new
oral fluoropyrimidines, synthesized with aim to overcome compli-
cations related to continuous infusion, central venous catheters,
and large variations in 5-FU bioavailability that made it inappro-
priate for oral administration. In that sense, two strategies were
developed. The first one was combining oral fluoropyrimidine
(tegafur) with dihydropyrimidine dehydrogenase inhibitor (enilu-
racil) (UFT). Another one was synthesis of the molecule, which
can be activated on its way to the malignant cell, which was actu-
ally achieved with capecitabine (Xeloda). After gastrointestinal
absorption capecitabine is hydrolyzed in the liver by car-
boxylesterase to produce 5’-Deoxy-5-Fluorocytidine, and this
molecule is then deaminated by cytidine deaminase, an enzyme
located primarily in hepatic and neoplastic tissue, to produce 5’-
Deoxy-5-Fluorouridine. The last enzymatic step, selective tumor
activation of 5’-Deoxy-5-Fluorouridine to 5-FU is catalyzed by
thymidine phosphorilase, thus minimizing systemic exposure to
5-FU (6). Level of thymidine phosphorilase is higher in most solid
tumors than in the corresponding normal tissues. Capecitabine
has demonstrated a high activity in preclinical xenograft models
of colorectal, breast, gastric and cervical cancer (7,8).  During
last several years capecitabine has been investigated in numer-
ous phase III clinical trials and compared with standard 5-FU
based protocols. Results of these studies (9,10), which com-
pared efficacy of capecitabine and standard protocols with 5-
FU/FA in first-line therapy of MCRC,  show that capecitabine is
more effective than Mayo Clinic protocol and equally effective as
de Gramon and German AIO infusion schemes. It also has signif-
icantly less toxic adverse events, apart from "hand and foot" syn-
drome. These results were the basis for initiation of study in three
Yugoslav centers, aimed to investigate efficacy and tolerability of
Xeloda monotherapy as first-line therapy of MCRC (11,12).
PATIENTS/MATERIALS AND METHODS
Between January 2000 and May 2001, three centers in Serbia
included 54 patients with MCRC; 38 males and 16 females, aged
30-78 years (Table 1); In 33 patients (61%) primary tumor was
located in colon, whilst in 21 (39%) it was located in rectum. All
patients had metastatic CRC, and in 28 (54%) of them this was
the initial episode of metastatic disease (Table 2). 
All patients received Xeloda in dose of 2500 mg/m2/day divided
in two daily doses, during 14 days, followed by 7 days of pause,
when the cycle was repeated at the same dosage. For disease
evaluation the WHO criteria and tumor markers CEA and CA 19-9
were used. Tumor markers were elevated in u 50 (98%) patients.
A subgroup of 29 patients had liver dysfunction before trial start -
defined as abnormal liver function tests (elevated bilirubin,
transaminase, gama-GT and/or alkaline phosphatase); five
patients had elevated total bilirubin > 5xUNL (upper normal limit).
Study procedures were performed in accordance with the ethical
standards of the Helsinki Declaration (1964, amended in 1975
and 1983) of the World Medical Association.
RESULTS 
Out of 54 enrolled patients, 47 were evaluable for efficacy. There
were total of 304 capecitabine cycles conducted with median of
6 cycles (range 1-9) per patient. Dose intensity for the whole
group was 88.79% +/- 9.27 (63.73 - 102.96). Overall response
rate (ORR) was 47%, with 13 % (6/47) of complete responses
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Table 1. Demographic data
Table 2. MCRC baseline status(CR),  34% (16/47) of partial responses, 38% (18/47) of stable
disease (SD) and 15% (7/47) of diseased progression (PD)
(Figure 1). 
There was no statistically significant difference in therapeutic
response between patients’ localization of primary tumor in colon
and those with tumor localized in rectum, nor with regard to the
free interval from operation to appearance of metastases. There
was no significant difference in therapeutic response in a sub-
group of 27 patients with recorded adverse effects of
capecitabine (’hand and foot’ syndrome and diarrhea) (Figure 2).
There was statistically significant difference (c2=8.06;
p<0.005) in response rate comparing 26 evaluable patients with
initial signs of liver dysfunction, i.e. those with elevated bilirubin
or transaminases, gama-GT and/or alkaline phosphatase at the
beginning of treatment, and those without liver dysfunction
(Figure 3). The most common adverse events were ’hand and
foot’ syndrome (in 52% patients, 26/47) and diarrhea (in 24%
patients, 12/47), or both (in 14% patients, 7/47). Other grade 2
toxicities were reported sporadically, with hematological toxicity
being more pronounced in a subgroup of patients with liver dys-
function (Z=-2.72; p<0.007). Global assessment of safety done
by investigators showed capecitabine tolerability profile was eval-
uated as ’excellent’ or ’very good’ in 70% of patients.
DISCUSSION
Oral use of capecitabine, with equal efficacy as 5-Fluorouracil and
leucovorin infusion regimens, is more convenient from patients’
point of view, primarily due to better comfort, lack of central
venous catheter placement and numerous possible complications
related to this procedure. Besides, during treatment a patient can
continue with daily activities. Overall response rate in this study
was surprisingly high. It should be noted that dose intensity was
almost ideal, but also the fact that response evaluation was per-
formed according to the WHO criteria in each center without eval-
uation of an independent committee (13). In addition, for efficacy
evaluation the level of tumor markers as additional criteria was
incorporated, so that a CR could not be assigned without normal-
ization of tumor markers, which were elevated in 98% of patients
before treatment start. Similarly, a partial response (PR) with
increased tumor markers was considered a SD, while SD with
increased tumor markers of over 50% was regarded a PD. On the
other hand, a SD with decreased tumor markers by over 50% was
regarded as PR. By additional analysis of response rate without
evaluation of tumor markers, no significant difference in response
rate was found.
It was surprising that no statistical significance in response rate
was found between patients with primary tumor at different loca-
tions, colon and rectum, considering evident difference in biolog-
ical characteristics of these tumors (14).
In some patients with CR, grade III adverse effects (hand and foot
syndrome) were reported. This has brought us to thinking that
perhaps patients with pronounced adverse effects have better
therapeutic response due to longer drug clearance, which pro-
vides longer drug exposure of tumor tissue (15). On the other
hand it is possible that therapeutic response in these patients can
be worse because adverse effects can lead to dose modification
or increased dose interval between cycles, which can further lead
Xeloda in metastatic colorectal carcinoma
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Figure 1. Response rate
Figure 2. Response rate in patinets with adverse events
Figure 3. Response rate in patinets with liver dysfunctionto lower dose intensity. However, in our patients adverse events
did not have any adverse influence on therapeutic response
(Figure 2).
Response analysis in a subgroup of patients with liver dysfunc-
tion showed statistically significantly lower overall response in
these patients (Figure 3) as compared to the remaining patients
with normal liver function. Earlier evaluation of the effect of treat-
ment in patients with hyperbilirubinemia induced by liver metas-
tases indicated relative safety of capecitabine administration in
these patients and possibility of its use in this patient group (11).
Capecitabine monotherapy has been proved as safe without sig-
nificant adverse events. The expected capecitabine adverse
events included diarrhea or ’hand and foot’ syndrome or both
adverse events in majority of our patients. However, these
adverse events were reversible, easily managed with sympto-
matic treatment and did not require therapy withdrawal, except in
one patient with total colectomy and huge small bowel resection
with consequent malabsorption and uncontrolled diarrheas.
Hematological toxicity was most prominent in 5 patients with ini-
tial hyperbilirubinemia. These results have proved once again that
liver metastases and liver dysfunction represent poor prognostic
signs in treatment of these patients.
Thanks to its pharmacokinetic and pharmacodynamic properties
by which it imitates continuous 5-FU infusion with significantly
less adverse events and at least equal efficacy, capecitabine is a
medicine that probably could replace 5-FU in standard MCRC
treatment protocols. On the other side we should wait for results
of numerous clinical trials with combination of capecitabine and
other agents in order to define its precise place in treatment of
MCRC. Anyway, according to the results of this study
capecitabine is a good monotherapy option as first line therapy of
MCRC.
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